What does Fujian Haixi Pharmaceuticals Co., Ltd. do?

Fujian Haixi Pharmaceuticals Co., Ltd. (2637.HK) operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

What is 2637.HK's market cap?

Fujian Haixi Pharmaceuticals Co., Ltd. (2637.HK) has a market capitalization of approximately $15.74 billion, as of August 25, 2026, based on the most recent share price and shares outstanding.

Does 2637.HK pay a dividend?

No — Fujian Haixi Pharmaceuticals Co., Ltd. (2637.HK) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.

2637.HK (Fujian Haixi Pharmaceuticals Co., Ltd.) is a recent IPO.

It began trading on December 8, 2025, giving it less than a year of public history. Many charts and metrics below are sparse or empty until more price, financial, and analyst history accumulates — the affected sections are flagged individually so you can tell limited history from missing data.

2637.HK

Fujian Haixi Pharmaceuticals Co., Ltd.

HKSE·Drug Manufacturers, Specialty & Generic · Healthcare

HK$200.00HK$6.10+3.15%

Market capHK$15.74B·Aug 25 8:08 AM UTC

Frequently Asked Questions About 2637.HK

What does Fujian Haixi Pharmaceuticals Co., Ltd. do?: Fujian Haixi Pharmaceuticals Co., Ltd. (2637.HK) operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is 2637.HK's market cap?: Fujian Haixi Pharmaceuticals Co., Ltd. (2637.HK) has a market capitalization of approximately $15.74 billion, as of August 25, 2026, based on the most recent share price and shares outstanding.
Does 2637.HK pay a dividend?: No — Fujian Haixi Pharmaceuticals Co., Ltd. (2637.HK) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.

2637.HK (Fujian Haixi Pharmaceuticals Co., Ltd.) is a recent IPO.

2637.HK

Fujian Haixi Pharmaceuticals Co., Ltd.

HKSE·Drug Manufacturers, Specialty & Generic · Healthcare

HK$200.00HK$6.10+3.15%

Market capHK$15.74B·Aug 25 8:08 AM UTC

Price Chart

HK$200.00+HK$6.10 (+3.15%)today

+53.37%

Select date range

FromTo

Dec 8, 2025Dec 8, 2025 → Aug 25, 2026· 9 moAug 25, 2026

Key Metrics

2637.HK does not currently pay a dividend.

EarningsEarnings Tab

EPS (FWD)—

P/E Ratio (FWD)—

EPS Growth (1Y)—

EPS Growth (3Y)—

EPS Growth (5Y)—

Next Earnings Date—

Last Report Date—

Reported vs Estimate—

Earnings Surprise—

Income Statement Flow

PRO

See exactly how 2637.HK's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.

The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 2637.HK and 80,000+ other tickers.

About Fujian Haixi Pharmaceuticals Co., Ltd.

Fujian Haixi Pharmaceuticals Co., Ltd. engages in research and development, production, and sale of pharmaceutical products in China. The company offers drugs for oncology, ophthalmology, respiratory, digestion, cardiovascular, endocrine, and nervous systems, and inflammation. It also provides pharmaceuticals technical services. In addition, the company offers generic alternatives, such as Anbili, a generic of mosapride citrate tablets; Haihuitong 5mg/10mg and 5mg/20mg, a generic of amlodipine besilate and atorvastatin calcium tablets; Ruiantuo, a generic of cinacalcet hydrochloride tablets…

CEO: Xinshan Kang
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Exchange: HKSE
Employees: 200
Website: www.hxpharma.com

Latest News

News Tab

No recent news available.

Frequently Asked Questions About 2637.HK

What does Fujian Haixi Pharmaceuticals Co., Ltd. do?: Fujian Haixi Pharmaceuticals Co., Ltd. (2637.HK) operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is 2637.HK's market cap?: Fujian Haixi Pharmaceuticals Co., Ltd. (2637.HK) has a market capitalization of approximately $15.74 billion, as of August 25, 2026, based on the most recent share price and shares outstanding.
Does 2637.HK pay a dividend?: No — Fujian Haixi Pharmaceuticals Co., Ltd. (2637.HK) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.